Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.71 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.71 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464902 | 1.00 | EGFR (0.71) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL30249910 | 0.91 | ALDH1A1 (0.59) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL4600832 | 0.90 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL10413058 | 0.90 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL4600830 | 0.90 | EGFR (0.85) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL29382887 | 0.87 | ALDH1A1 (0.55) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL437568 | 0.83 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| SCHEMBL8749181 | 0.83 | EGFR (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26825 | 0.83 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 | |
| Alpha-Cyano-4-Hydroxycinnamic Acid SCHEMBL26826 | 0.83 | KDM4E (1.00) | EGFRCISD1KDM4ESLC16A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542897-B1 | Use of halogenated cyanocinnamic acid derivatives as matrices in MALDI mass spectrometry | SIGMA ALDRICH INTERNAT GMBH (CH) | 2015-06-17 | — | — | EP | claimed |
| US-20130040395-A1 | USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2013-02-14 | — | — | US | claimed |
| EP-2542897-A1 | USE OF HALOGENATED CYANOCINNAMIC ACID DERIVATIVES AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2013-01-09 | — | — | EP | claimed |
| WO-2011107076-A1 | USE OF HALOGENATED CYANOCINNAMIC ACID DERIVATIVES AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2011-09-09 | — | — | WO | claimed |
| US-20250102517-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12135330-B2 | Articles and methods involving detection of binding | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4407317-A2 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | Charles River Laboratories, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-3601609-B1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | CHARLES RIVER LABORATORIES INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3601609-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | Samdi Tech, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183482-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | SAMDI TECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| EP-2780330-B1 | 1-PYRIDAZINYL-HYDROXYIMINO- 3- PHENYL- PROPANES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-01-06 | — | — | EP | disclosed |
| US-9090565-B2 | 1-pyridazinyl-hydroxyimino-3-phenyl-propanes | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2011107076-A1 | USE OF HALOGENATED CYANOCINNAMIC ACID DERIVATIVES AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2011-09-09 | — | — | WO | disclosed |
| EP-1565464-B1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-07-23 | — | — | EP | disclosed |
| US-7342024-B2 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROST CANADA LTD. (CA) | 2008-03-11 | — | — | US | disclosed |
| US-7238706-B2 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-03-16 | — | — | US | disclosed |
| EP-1565464-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-24 | — | — | EP | disclosed |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | MERCK CANADA INC. (CA) | 2005-05-19 | — | — | US | disclosed |
| WO-2004048374-A1 | 4-OXO-1-(3-SUBSTITUTED PHENYL-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040395-A1 | USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY | DOHH, DBH, CBR3 | EGFR 1800/4885CISD1 65/4885KDM4E 3943/4885 |
| US-20050107402-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | EGFR 4574/4885CISD1 3357/4885KDM4E 448/4885 |
| US-20060058316-A1 | 4-Oxo-1-3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | EGFR 4654/4885CISD1 2684/4885KDM4E 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.